Steven Cohen’s Acadia Pharmaceuticals ACAD Stock Holding History

Steven Cohen’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$359K	Buy	14,200 +500	+4%	+$11K	﹤0.01%	3319
2026 Q1	$305K	Buy	+13,700	New	+$327K	﹤0.01%	3358
2018 Q2	–	Sell	-400,000	Closed	-$8.99M	–	943
2018 Q1	$8.99M	Buy	+400,000	New	+$11.1M	0.04%	448
2017 Q4	–	Sell	-500,000	Closed	-$18.8M	–	882
2017 Q3	$18.8M	Buy	+500,000	New	+$16.3M	0.08%	273

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Steven Cohen's ACAD Position: Q2 2026 in Review

Steven Cohen reduced its Acadia Pharmaceuticals (ACAD) stake by 5.6% in Q2 2026, selling an estimated $3.18M and leaving 2,433,168 shares worth $61.6M. The position accounts for 0.07% of the portfolio, ranked #354.

Steven Cohen first reported a position in ACAD in Q2 2014 and has held it in 39 quarters since. The position peaked at $97.9M in Q1 2018. 350 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Steven Cohen held 2,433,168 shares of Acadia Pharmaceuticals worth $61.6M as of Q2 2026.
Steven Cohen sold 144,748 Acadia Pharmaceuticals shares in Q2 2026, an estimated $3.18M.
Acadia Pharmaceuticals made up 0.07% of Steven Cohen's portfolio in Q2 2026, its #354 holding.
Steven Cohen first reported a position in Acadia Pharmaceuticals in Q2 2014 and has held it in 39 quarters since.
Steven Cohen's Acadia Pharmaceuticals position peaked at $97.9M in Q1 2018.
350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.